Voyager Therapeut (VYGR)

$4.16 +0.15 (3.87%)
Market Cap 222.15M
Revenue (ttm) 80.00M
Net Income (ttm) -65.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -81.25%
Debt to Equity Ratio 0.00
Volume 654,900
Avg Vol 715,714
Day's Range N/A - N/A
Shares Out 55.47M
Stochastic %K 80%
Beta 0.90
Analysts Strong Sell
Price Target $15.08

Company Profile

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amy...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 259 5340
Address:
75 Hayden Avenue, Lexington, United States
BigDaddyPumper
BigDaddyPumper Sep. 10 at 7:04 PM
$VYGR What an awesome looking chart. Just continues to climb while setting solid bases.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 10 at 5:40 AM
$VYGR Outstanding article that hits the mark on VYGR's current state. So if you want to refresh your VYGR insights or learn about VYGR from scratch, this is a must read. https://beyondspx.com/quote/VYGR/analysis/voyager-therapeutics-pioneering-precision-in-neurogenetic-medicine-nasdaq-vygr
0 · Reply
kshonstocks
kshonstocks Sep. 5 at 4:59 PM
$VYGR 200 dma b/o
0 · Reply
DonkeyPuncherDude
DonkeyPuncherDude Sep. 5 at 2:04 PM
$VYGR
0 · Reply
WestEgg
WestEgg Sep. 5 at 1:43 PM
$VYGR hopeful for B/O
0 · Reply
jm4
jm4 Sep. 4 at 11:19 PM
$VYGR
0 · Reply
0fabiocoppola
0fabiocoppola Sep. 4 at 9:54 PM
$VYGR will go to the moon
0 · Reply
BigDaddyPumper
BigDaddyPumper Sep. 3 at 1:58 PM
$VYGR Steady steps, forming solid bases since may. This is heading back to 8$+.
0 · Reply
Wolf0vs
Wolf0vs Sep. 2 at 1:51 PM
$VYGR
0 · Reply
St0ckt0k101
St0ckt0k101 Aug. 23 at 12:52 AM
$VYGR looking to buy in next week! Small position but doing my DD this week!! Looks very promising folks, have a great weekend!
1 · Reply
Latest News on VYGR
Voyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 6:23 PM EDT - 8 days ago

Voyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference Transcript

Voyager to Present at Upcoming Investor Conferences

Aug 26, 2025, 7:00 AM EDT - 15 days ago

Voyager to Present at Upcoming Investor Conferences

Voyager Reports Second Quarter 2025 Financial and Operating Results

Aug 6, 2025, 4:01 PM EDT - 5 weeks ago

Voyager Reports Second Quarter 2025 Financial and Operating Results

Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

Jul 16, 2025, 7:00 AM EDT - 2 months ago

Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 10, 2025, 7:00 AM EDT - 3 months ago

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

May 15, 2025, 7:00 AM EDT - 4 months ago

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

Voyager Reports First Quarter 2025 Financial and Operating Results

May 6, 2025, 4:01 PM EDT - 4 months ago

Voyager Reports First Quarter 2025 Financial and Operating Results

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

Apr 28, 2025, 4:30 PM EDT - 4 months ago

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

Mar 31, 2025, 7:00 AM EDT - 5 months ago

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

Voyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:35 PM EDT - 6 months ago

Voyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call Transcript

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Mar 11, 2025, 4:01 PM EDT - 6 months ago

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

Mar 4, 2025, 7:00 AM EST - 6 months ago

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease

Mar 3, 2025, 7:00 AM EST - 6 months ago

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease

The Schall Law Firm Invites Shareholders With Losses In Voyager Therapeutics, Inc. To Join A Securities Fraud Investigation

Mar 2, 2025, 11:00 AM EST - 6 months ago

The Schall Law Firm Invites Shareholders With Losses In Voyager Therapeutics, Inc. To Join A Securities Fraud Investigation

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

Feb 25, 2025, 7:00 AM EST - 7 months ago

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Feb 21, 2025, 10:51 PM EST - 7 months ago

VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Voyager Provides Update on SOD1 ALS Gene Therapy Program

Feb 11, 2025, 7:00 AM EST - 7 months ago

Voyager Provides Update on SOD1 ALS Gene Therapy Program

Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance

Jan 30, 2025, 5:06 PM EST - 7 months ago

Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance

Voyager Therapeutics, Inc. (VYGR) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 11:07 PM EST - 10 months ago

Voyager Therapeutics, Inc. (VYGR) Q3 2024 Earnings Call Transcript

Voyager Reports Third Quarter 2024 Financial and Operating Results

Nov 12, 2024, 4:01 PM EST - 10 months ago

Voyager Reports Third Quarter 2024 Financial and Operating Results

Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

Nov 5, 2024, 7:00 AM EST - 11 months ago

Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 29, 2024, 4:01 PM EDT - 1 year ago

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Voyager: Anti-Tau Antibody Differentiation For AD Treatment Could Boost Prospects

Aug 26, 2024, 3:24 PM EDT - 1 year ago

Voyager: Anti-Tau Antibody Differentiation For AD Treatment Could Boost Prospects

Voyager Therapeutics, Inc. (VYGR) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 5:43 AM EDT - 1 year ago

Voyager Therapeutics, Inc. (VYGR) Q2 2024 Earnings Call Transcript

Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

Jun 13, 2024, 4:01 PM EDT - 1 year ago

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

Jun 13, 2024, 7:00 AM EDT - 1 year ago

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

The 'Undercovered' Dozen From June 1-6

Jun 7, 2024, 6:26 PM EDT - 1 year ago

The 'Undercovered' Dozen From June 1-6

ALNY CLOV CRSP ENVX GAM HAL LPA

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Jun 5, 2024, 11:52 AM EDT - 1 year ago

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

3 Biotech Names Under $10 I Own

Jun 2, 2024, 10:18 AM EDT - 1 year ago

3 Biotech Names Under $10 I Own

AUPH FOLD

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer's Disease

May 16, 2024, 7:00 AM EDT - 1 year ago

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer's Disease

Voyager Therapeutics, Inc. (VYGR) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:43 AM EDT - 1 year ago

Voyager Therapeutics, Inc. (VYGR) Q1 2024 Earnings Call Transcript

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

May 13, 2024, 4:01 PM EDT - 1 year ago

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

May 8, 2024, 6:00 AM EDT - 1 year ago

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

BigDaddyPumper
BigDaddyPumper Sep. 10 at 7:04 PM
$VYGR What an awesome looking chart. Just continues to climb while setting solid bases.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 10 at 5:40 AM
$VYGR Outstanding article that hits the mark on VYGR's current state. So if you want to refresh your VYGR insights or learn about VYGR from scratch, this is a must read. https://beyondspx.com/quote/VYGR/analysis/voyager-therapeutics-pioneering-precision-in-neurogenetic-medicine-nasdaq-vygr
0 · Reply
kshonstocks
kshonstocks Sep. 5 at 4:59 PM
$VYGR 200 dma b/o
0 · Reply
DonkeyPuncherDude
DonkeyPuncherDude Sep. 5 at 2:04 PM
$VYGR
0 · Reply
WestEgg
WestEgg Sep. 5 at 1:43 PM
$VYGR hopeful for B/O
0 · Reply
jm4
jm4 Sep. 4 at 11:19 PM
$VYGR
0 · Reply
0fabiocoppola
0fabiocoppola Sep. 4 at 9:54 PM
$VYGR will go to the moon
0 · Reply
BigDaddyPumper
BigDaddyPumper Sep. 3 at 1:58 PM
$VYGR Steady steps, forming solid bases since may. This is heading back to 8$+.
0 · Reply
Wolf0vs
Wolf0vs Sep. 2 at 1:51 PM
$VYGR
0 · Reply
St0ckt0k101
St0ckt0k101 Aug. 23 at 12:52 AM
$VYGR looking to buy in next week! Small position but doing my DD this week!! Looks very promising folks, have a great weekend!
1 · Reply
Estimize
Estimize Aug. 20 at 8:00 PM
Wall St is expecting -0.52 EPS for $VYGR Q3 [Reporting 11/18 AMC] http://www.estimize.com/intro/vygr?chart=historical&metric_name=eps&utm_c
0 · Reply
DonkeyPuncherDude
DonkeyPuncherDude Aug. 18 at 5:51 PM
$VYGR If you actually read the filings, it was for tax obligations, you moron. Reported and blocked.
2 · Reply
outlawinvestor1
outlawinvestor1 Aug. 16 at 10:32 PM
$VYGR this company looked promising until I saw all of the mgmt/bod selling that’s taken place over the last few years. If they don’t believe it enough to buy, i wouldn’t want to either.
0 · Reply
Orlandotrader
Orlandotrader Aug. 15 at 4:18 PM
$VYGR Gonna need some News to Break this out. Lots of Potential and big Pharma Relationships. Four Programs ready to Ramp up. Definitely a 2026 Story.
0 · Reply
lob11
lob11 Aug. 13 at 5:23 PM
$VYGR see if it can push past the $3.75 sell wall
2 · Reply
DonkeyPuncherDude
DonkeyPuncherDude Aug. 13 at 4:01 PM
$VYGR
0 · Reply
juicy123
juicy123 Aug. 13 at 3:47 PM
$VYGR there are short squeeze or what is going on here?
0 · Reply
JarvisFlow
JarvisFlow Aug. 7 at 1:00 PM
Wedbush has adjusted their stance on Voyager Therapeutics ( $VYGR ), setting the rating to Outperform with a target price of 9 → 8.
0 · Reply
Estimize
Estimize Aug. 7 at 12:09 AM
$VYGR reported -0.57 EPS and 5.20 revenue for Q2. http://www.estimize.com/intro/vygr?chart=historical&metric_name=eps&utm_content=VYGR&utm_
0 · Reply
dotttodott
dotttodott Aug. 6 at 10:05 PM
$VYGR Thoughts on Q2 earnings? Will it rise with the confidence in long-term cash runway?
1 · Reply
dotttodott
dotttodott Aug. 6 at 9:53 PM
$VYGR Q2 Results in: https://www.globenewswire.com/news-release/2025/08/06/3128626/36461/en/Voyager-Reports-Second-Quarter-2025-Financial-and-Operating-Results.html
1 · Reply
rainman_or
rainman_or Aug. 5 at 10:10 PM
$VYGR when are Q2 2025 earnings going to be released?
4 · Reply